ClinicalTrials.gg

Papillomavirus Infections clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 580 studies for Papillomavirus Infections across more than 10 countries. 133 are recruiting or about to start. 386 of them are mainly about Papillomavirus Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 3 narrower conditions too, such as Warts: 850 studies, 177 open.

ClinicalTrials.gov finds 969 studies for Papillomavirus Infections. How that becomes 575 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Papillomavirus Infections, and those it files under no condition that list Papillomavirus Infectionsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 969Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −189Filed under a narrower condition, counted on its own pageWarts 112 · Condylomata Acuminata 76
  3. −6List Papillomavirus Infections as a condition, but the registry did not file them under itMost often written as “Anal Canal HPV Infection Diagnosis” (1), “Cervical Persistent High Risk HPV Infection” (1), and “AIDS-Related Human Papillomavirus Infection” (1). The registry filed them under other conditions only, most often Uterine Cervical Dysplasia (2) and HIV Infections (2).
  4. −199Match it another way51 name it in the title, 2 in a keyword, and 146 by a synonym or other text the search reads.
  5. 575The count on this page9 of them list Papillomavirus Infections in their own words; the registry filed them under no condition.

Status

Completed
308
Recruiting
87
Active, not recruiting
57
Status unknown
49
Not yet recruiting
41
Terminated
18

Phase

Phase 3
101
Phase 2
94
Phase 1
39
Phase 4
35
Early Phase 1
3

Where

United States
166
China
67
France
28
Canada
25
Spain
21
Italy
21

Who develops what

Add Papillomavirus Infections to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 14 programs from 12 companies, 6 with this as their studies’ main aim; 3 with a live phase 3 study; 6 primary completions in the next 12 months. Compare Merck, PT Bio Farma and Serum Institute of India Pvt. here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Human Papillomavirus Recombinant Vaccine nonavalentRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07888686 · Serum Institute of India Pvt. Ltd. · Phase 2 · live · comparator · “Gardasil9” · registered Sep 2026
  • NCT06207175 · Beijing Health Guard Biotechnology, Inc · Phase 3 · live · comparator · “GARDASIL® 9” · registered Jan 2024
  • NCT05662020 · Beijing Health Guard Biotechnology, Inc · Phase 3 · live · comparator · “GARDASIL® 9” · registered Dec 2022
  • NCT05580341 · Shanghai Zerun Biotechnology Co.,Ltd · Phase 3 · comparator · “GARDASIL ®9” · registered Oct 2022
  • NCT05372016 · Shanghai Bovax Biotechnology Co., Ltd. · Phase 3 · comparator · “Active Comparator: GARDASIL ®9” · registered Dec 2020
Merck & Co., Inc80% of its industry studies34 studies

4 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Tetanus-Diphtheria booster☆ Track1 live phase-3 study: NCT07824310PT Bio Farma
Human Papillomavirus Recombinant Vaccine nonavalentPhase 4 trial recorded☆ Track6 live phase-3 studies: NCT07785843, NCT04199689, NCT03998254Merck & Co., Inc

The 2 in phase 3 with the nearest primary completion, of 14 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (6)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 27 Dec 2026 est.epigallocatechin gallate · Amplexd Therapeutics, Inc. · Phase 2 named, not the main aimNCT07572396 Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities — primary endpoint: To determine and evaluate the safety and tolerability of Dysplasix™ intravaginal suppository therapy in females with hr-HPV and positive cytology for either ASCUS or LSIL. · 45 enrolled
  • 31 Dec 2026 est.Tetanus-Diphtheria booster · PT Bio Farma · Phase 3 main aimadded to Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18NCT07824310 Immunogenicity and Safety of HPV-4 Vaccine With or Without Td Vaccine in Children — primary endpoint: Number and percentage of subjects seroconverted for anti-HPV types 6, 11, 16, and 18 · 266 enrolled
  • 15 Jan 2027 est.Human Papillomavirus Recombinant Vaccine nonavalent · Merck & Co., Inc · Phase 3 main aimNCT04199689 Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) — primary endpoint: Incidence of HPV 16/18/31/33/45/52/58-related 6-month Persistent Oral Infection · 6,033 enrolled

3 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Papillomavirus Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 1 open · Antimitotic agents 3

Coming up

65studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger. 19 (22%) take children under 18. 56 (64%) are for women only and 3 (3%) for men only; 36 (41%) take healthy volunteers.

Recruiting studies that take each age, of 87
AgeWomenMen
1016 (18%)6 (7%)
1846 (53%)24 (28%)
3075 (86%)22 (25%)
4077 (89%)24 (28%)
5066 (76%)22 (25%)
6557 (66%)22 (25%)
7543 (49%)20 (23%)
8541 (47%)19 (22%)

Across all 580 studies, recruiting or not: 65% stop at 75 or younger and 62% at 65; 30% take children; 67% are for women only and 5% for men only; 58% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Papillomavirus Infections studies take

Of 60 phase 3 interventional studies under Papillomavirus Infections, half reached primary completion within 29 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 117 mo13–25 · 16 studies——
Phase 233 mo13–77 · 41 studies——
Phase 329 mo16–67 · 60 studies24 mo13–64 · 54 studies—
Phase 462 mo20–92 · 28 studies——
Interventional, no phase26 mo11–48 · 117 studies—26 mo11–48 · 108 studies
Observational46 mo24–90 · 66 studies—49 mo24–92 · 53 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 580. Browse all 580 → or search them.